Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Tax Rate (2021 - 2025)

Historic Tax Rate for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to 32.12%.

  • Kiniksa Pharmaceuticals International's Tax Rate rose 1083800.0% to 32.12% in Q3 2025 from the same period last year, while for Sep 2025 it was 26.13%, marking a year-over-year increase of 177300.0%. This contributed to the annual value of 19.48% for FY2024, which is 532000.0% down from last year.
  • According to the latest figures from Q3 2025, Kiniksa Pharmaceuticals International's Tax Rate is 32.12%, which was up 1083800.0% from 22.05% recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Tax Rate ranged from a high of 1308.39% in Q2 2023 and a low of 379.5% during Q3 2022
  • For the 5-year period, Kiniksa Pharmaceuticals International's Tax Rate averaged around 61.59%, with its median value being 0.43% (2021).
  • Per our database at Business Quant, Kiniksa Pharmaceuticals International's Tax Rate surged by 13121100bps in 2023 and then crashed by -10387800bps in 2024.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Tax Rate (Quarter) stood at 0.64% in 2021, then surged by 511bps to 2.62% in 2022, then soared by 1108bps to 31.63% in 2023, then soared by 51bps to 47.65% in 2024, then crashed by -33bps to 32.12% in 2025.
  • Its Tax Rate stands at 32.12% for Q3 2025, versus 22.05% for Q2 2025 and 45.14% for Q1 2025.